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Abstract
Introduction: In selected patients, radiofrequency ablation (RFA) is a well-established treatment for
hepatocellular carcinoma (HCC). However, subcapsular or lesions close to adjacent viscera preclude a
percutaneous approach. In this setting laparoscopic-RFA (LRFA) is a potential alternative. The aim of this
study was to analyse the safety and feasibility of LRFA in patients with HCC.
Patients and Methods: Retrospective study of patients with HCC meeting strict inclusion criteria who
underwent LRFA at a single Institution from December 2000 to March 2013.
Results: Forty-one patients underwent 42 LRFA of 51 nodules. The median size of the nodule was 2.5
(range 1.2–4.7) cm. Thirty-one tumours were subcapsular and 17 located near the gallbladder. Major
complications occurred in 17 patients. The initial complete response (ICR) rate was 94% and was lower
among tumours located adjacent to the gallbladder. At the end of the follow-up period, the sustained
complete response (SCR) rate was 70% and was lower in tumours adjacent to the gallbladder while
increased for subcapsular tumours. The 1-, 3- and 5-year overall survival rate was 92.6%, 64.5% and
43%, respectively.
Conclusion: LRFA of HCC is safe, feasible and achieves excellent results in selected patients. LRFA
should be the first-line technique for subcapsular lesions as it minimizes the risk of tumoural seeding and
improves ICR. Proximity to gallbladder interferes in treatment efficacy (lower rate of ICR and lower rate of
SCR).
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Introduction
Hepatocellular carcinoma (HCC) represents the sixth most preva-
lent cancer and the third most frequent cause of cancer-related
death.1 Liver transplantation (LT) remains the ideal treatment in
cirrhotic patients as it removes the tumour and cures the under-
lying liver disease, achieving excellent long-term results in selected
candidates.2
However, as a result of the organ scarcity and extent of disease,
liver transplantation remains an option for a minority of patients.
For the remainder of patients with HCC, alternative curative
treatment options include liver resection in selected patients with
preserved hepatic function or ablative therapies.3,4
Percutaneous radiofrequency ablation (pRFA) is the preferred
ablative therapy as it achieves better local tumour control and
survival results.5 Alternatively when RFA is not technically fea-
sible, percutaneous ethanol injection (PEI) can be considered.
Three non-concordant randomized controlled studies compar-
ing pRFA and hepatic resection have been published.6–8 Although
RFA seems safer, its efficacy in terms of tumour destruction is less
predictable and the reported incidence of late local recurrence
ranges from 1.7% to 41%.9 Factors influencing recurrence rates
after pRFA have included tumour size, Child–Pugh staging and
the initial response to RFA.10,11
Relative contraindications to pRFA include tumour location
(subcapsular lesions jeopardizing tumoral seeding or proximity to
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adjacent structures or viscera) or an inability to visualize the
tumour by percutaneous ultrasound (US).12–14 In such situations a
laparoscopic approach with RFA (LRFA) would appear to be an
appealing alternative especially in patients with moderately
impaired liver function.15
The aim of this study was to analyse the safety and feasibility of
LRFA for a selected group of patients with HCC. Indications,
patient morbidity, efficacy and survival were evaluated.
Patients and methods
Study design
From December 2000 to March 2013, a retrospective study of
patients undergoing LRFA for HCC performed in the Hospital
Clinic in Barcelona was conducted.
Pre-operative patient and tumour characteristics, intra-
operative details and post-operative outcomes including compli-
cations, treatment effectiveness and long-term outcomes were
evaluated.
The inclusion criteria for LRFA were as follows: patients with a
single nodule or up to three nodules <3 cm not suitable for liver
transplantation (because of age or medical conditions). Patients
not candidates for liver resection (because of portal hypertension,
impaired liver function or medical conditions) in whom pRFA
was contraindicated due to any of the following reasons: (i)
nodules in proximity to the gallbladder, colon, stomach or other
viscera; (ii) anterior subcapsular lesions at risk of tumour seeding
due to direct needle insertion; (iii) nodules not visible by percu-
taneous US, and (iv) As bridge therapy in selected patients eligible
for liver transplantation as per the Milan Criteria.2
The procedure was performed under general anaesthesia with a
standard laparoscopic technique. Intra-operative laparoscopic
non-enhanced US was performed to assess residual liver and
confirm location of the tumour to be treated.
Although all tumours showed radiological features of HCC, a
needle biopsy was performed intra-operatively prior to the LRFA.
As the aim of the present study was an intention-to-treat analysis,
all nodules have been included.
In case of tumour proximity to abdominal viscera, a
laparoscopic retractor or surgical sponge were used to avoid
thermal injury during LRFA. An associated cholecystectomy was
performed during the same surgery and before the LRFA pro-
cedure, when the tumour was adjacent to the gallbladder and if
symptomatic lithiasis. In anterior subcapsular lesions in which no
liver parenchyma was interposed between the lesion and the RFA
needle, continuous aspiration was performed to avoid blood
spreading.
Radiofrequency ablation was then accomplished through a
17-gauge internally cooled-tip electrode with an exposed tip of 2
to 3 cm, connected to an electrical generator (Covidien® TM,
Dublin, Ireland). This electrode was placed into and in the periph-
ery of the lesion under US guidance. Several insertions to treat
overlapping zones were needed to complete the procedure. Tissue
impedance was monitored throughout the procedure, and the
maximum current was adjusted accordingly. A peristaltic pump
was used to infuse 0 to 5°C normal saline solution into the lumen
of the electrode at a rate to maintain a tip temperature <20°. The
appearance and progression of hyperechogeneity was used to
guide the duration of the therapy. After finishing the nodule
ablation, the intrahepatic needle track was treated by
thermocoagulation to avoid local seeding. The treatment was per-
formed without hepatic vascular inflow control.
One month after LRFA, all patients underwent a contrast-
enhanced study. Since 2006 contrast-enhanced ultrasound
(CEUS) has been the investigation of choice.16 Before that period,
four-phase contrast enhanced computered tomography (CT) or
magnetic resonance (MR) were employed.
After the imaging, the LRFA response was classified as an initial
complete response (absence of any enhancing areas within the
treated nodule) or an initial incomplete response (presence of
enhanced tissue in the tumour site). When the latter occurred,
either a new LRFA or an ablative percutaneous treatment was
performed depending on tumour size and location. Treatment
failure was defined by the persistence of active tumour foci after
three iterative procedures.
Three months after the initial procedure the contrast-enhanced
study was repeated to confirm tumour response, and thereafter
patients were followed every 6 months by CEUS, CT or MRI along
with the serum alpha-fetoprotein level.
A sustained complete response was defined by the absence of any
enhancing areas within the treated nodule at the end of follow-up.
Local recurrence was defined as the appearance, during follow-up,
of any enhancing tumour in a previously ablated area in which
complete necrosis had been achieved, or the appearance of a new
nodule within 1 cm of the ablation zone. Distant recurrence was
defined as any new progressive enhancing nodule distant to the
ablation zone located either intra or extrahepatically.
Follow-up was defined by the elapsed time between LRFA and
last clinical evaluation of the patient during the study period,
death of the patient or liver transplantation.
Post-operative complications were classified by the modified
Clavien–Dindo Classification system.17
Statistical analysis
Continuous variables were expressed as the median and the range
and compared using the Mann–Whitney U test. Chi-square or
Fisher’s exact tests was employed to compare categorical variables.
Patient actuarial survival was calculated using the Kaplan–Meier
method. A P-value under 0.05 was considered significant in all
tests. All statistical analyses were performed with the PASW Sta-
tistical Package Version 18.0 for Windows (SPSS Inc., Chicago, IL,
USA).
Results
Between December 2000 and March 2013, 41 consecutive patients
underwent 42 laparoscopic ablation procedures of 51 nodules.
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During the same period 332 patients underwent percutaneous
RFA ablation procedures for HCC. Patient and nodule character-
istics are shown in Table 1. Intra-operative US examination
detected additional nodules not identified in diagnostic workup in
four patients. Conversion to open surgery did not occur. Final
histological examination confirmed HCC in 48 nodules whereas
high grade dysplasia was present in 3 nodules.
Treatment-related complications: (Table 2)
Seventeen patients presented with post-operative complications
(Table 2). One patient underwent re-intervention as a result of
haemoperitoneum and four patients developed transient hepatic
decompensation. No injuries to abdominal viscera occurred. Neo-
plastic seeding was identified in one patient. This patient pre-
sented with two HCC: one nodule adjacent to the gallbladder
(persistent after three PEI sessions) and a newly-appeared
subcapsular lesion. A simultaneous laparoscopic cholecystectomy
was performed previous to LRFA of the two nodules and the
gallbladder was retrieved inside an endobag through the upper
right quadrant trocar incision. Tumoral seeding was identified at
the trocar location 13 months after LRFA and was surgically
excised. The patient developed local recurrence and distant
intrahepatic recurrence and died 20 months after the LRFA.
Table 1 Patient and nodule characteristics
Patient characteristics n = 41 Nodule characteristics n = 51
Variable Result Variable Result
Age (years) [median(range)] 67.5 (42–85) Number of nodules [median(range)] 1 (1–3)
Gender (M/F) 30/11 Unicentric n (%) 32 (78%)
Cause of cirrhosis (n)
Tumour location n (%)
– HCV 28
– Alcoholic disease 7 – Subcapsular 31 (60.8%)
– HBV 4 Adjacent to gallbladder 1 (1.9%)
– Other 2 Adjacent to other viscerae 7 (13.7%)
MELD [median(range)] 9 (6–19)
– Deep intrahepatic location 20 (39.2%)Child–Pugh (n)
– A 29
– B 9
Vascular contact 3 (5.8%)
Adjacent to gallbladder 15 (29.4%)
No contact 2 (3.9%)– C 1
Indication of RFA treatment (n)
Size of the largest tumour (cm) [median(range)] 2.5 (1.2–4.7)
– Primary treatment 18
– Bridge therapy pre-LT 11
– Secondary treatment n 23
Previous treatment (n) Categorized size of the largest tumour n (%)
– PEI 13 – ≤2 cm 18 (35.3%)
– TACE 1 – 2.1–3 cm 22 (43.1%)
– Percutaneous RFA 3
– 3.1–5 cm 11 (21.6%)
– TACE+PEI 1
– RFA+PEI 2
– Surgical resection 3
HCV, hepatitis C virus; HBC, hepatitis B virus; MELD, model for end-stage liver disease; RFA, radiofrequency ablation; LT, liver transplantation; PEI,
percutaneous ethanol injection; TACE, transartherial chemoembolization.
Table 2 Intra-operative characteristics and post-operative outcomes
Variable Result
Associated cholecystectomy (n) 17
Red blood cell transfusion (n) 0
Post-operative complications (n)
– Clavien I 7
– Clavien II 5
– Clavien IIIa 0
– Clavien IIIb 1
– Clavien IVa 4
– Clavien IVb 0
– Clavien V 0
Hospital stay (days) [median (range)] 3 (1–9)
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In univariate analysis, treatment-related complications (TRC)
were not associated with neither simultaneous cholecystectomy (9
TRC if associated cholecystectomy versus 8 TRC if not, P = 0.209)
nor Child–Pugh classification (10, 5 and 0 TRC in Child–Pugh A,
B and C patients respectively, P = 0.381).
Treatment response and outcomes: (Tables 3 and 4)
Initial complete response (ICR) and treatment failure
An initial complete response (ICR) was achieved in 48 of the 51
nodules and tumours located adjacent to the gallbladder were
significantly associated with a higher rate of ICR. Treatment failure
occurred in spite of iterative transartherial chemoembolization
(TACE) in two patients and PEI in one patient.
Local recurrence (LR), sustained complete response
(SCR) and distance recurrence (DR)
Local recurrence was diagnosed in 12 of the nodules after a
median delay of 9 (range 3.5–31.1) months. TACE was performed
in 3 of them and PEI, pRFA and intratumoral Y-90 in one patient
each. The restant patients presenting LR showed concomitant
multinodular DR and refused treatment.
By the end of follow-up period, SCR was evident in 36 tumours
of 30 patients, independently of tumour size or number of
nodules. Tumour location significantly affected SCR, as the rate of
SCR was diminished in nodules adjacent to the gallbladder while
increased in subcapsular lesions (Table 4).
DR occurred in 25 patients after a median interval of 8.1 (range
1.5–31.1) months after the LRFA (probably the earlier recurrences
were indeed understaged patients).
The rate of overall recurrence at 1, 3 and 5 years was 39.0%,
51.2% and 60.9%, respectively. Patients were offered TACE, PEI,
iterative pRFA, intratumoral Y-90 and sorafenib, either isolated or
combined, tailored in every case to the type of recurrence and
patient conditions.
Seven out of the eleven patients treated while on the waiting list,
were finally transplanted (one of them from a living donor).
Although none of them had shown LR or DR in imaging tech-
niques, all of them showed, at pathological examination, viable
cells in the treated tumour and in two cases incidental HCC not
previously diagnosed.
Survival
At the end of the follow-up period, 5 patients were lost and 15
patients had died all but two as a result of tumour progression.
Once excluded the 7 patients finally submitted to liver transplan-
tation, the 1-, 3- and 5-year overall survival rate was 92.6%, 64.5%
and 43%, respectively (Fig. 1). Survival was significantly associ-
ated with distant recurrence (a 5-year survival rate of 90.9% if no
distant recurrence occurred versus 38.4% if present; P = 0.046).
Discussion
RFA is a valid treatment option for very early and early HCC with
comparable results to surgical resection in selected patients.6,8,10
However, a tumour location adjacent to the gallbladder or other
viscera precludes a percutaneous approach because of the poten-
tial thermal injury and the consequent risk of perforation.14,18
These arguments, together with the high incidence of needle
track seeding associated with subcapsular lesions reported by our
group compared with others,12,13 justified the introduction of
laparoscopic RFA in our Centre.
Results in terms of tumoral seeding have markedly improved,
thus confirming the appropriateness of the laparoscopic approach
for the treatment of subcapsular lesions, which in the current
series are indeed, associated with a higher rate of SCR. In this
particular location, the laparoscopic technique offers a direct
vision of the entire procedure, allowing not only the isolation of
the tumour from the abdominal viscera, but also performing sim-
ultaneous procedures such as a cholecystectomy (in case of
nodules adjacent to the gallbladder) and the manoeuvre of
continuous aspiration of the blood emerging after the needle
insertion which could maybe explain the notable decrease in neo-
plastic seeding in the present series.
Table 3 Treatment response and outcome
Variable Result
Time to first tumour response evaluation
(days) [median (range)]
41 (21–109)
Imaging technique for first response
evaluation (n)
– CEUS 19
– CT scan 13
– MRI 5
– CEUS + MRI 4
First response evaluation: (n)
– Initial treatment failure 3
– Initial complete response 48
Follow-up evaluation: (n)
– Sustained complete response 36
– Local recurrence 12
– Distant recurrence 25
Intrahepatic 19
Extrahepatic 2
Intra- and extrahepatic 4
Follow-up (months) [median (range)] 33 (2.5–89.6)
Overall mortality (n) 15
Cause of mortality (n)
– Tumour progression 13
– Cirrhosis complications 1
– Others 1
CEUS, contrast-enhanced ultrasound; CT, computed tomography; MRI,
magnetic resonance imaging.
HPB 2015, 17, 387–393 ª 2014 International Hepato-Pancreato-Biliary Association
390 HPB
Although cirrhotic patients have a demonstrated increased
surgical risk in elective procedures compared with non-cirrhotic
patients,19 laparoscopy seems to minimize the surgical insult and
provides a faster recovery and shorter hospital stay.20 Lower
overall morbidity, lesser hepatic decompensation and blood loss,
and fewer pulmonary complications have been demonstrated
with this approach.20–22 Furthermore, capnopneumoperitoneum
adds a beneficial physiopathological effect to RFA as it decreases
the portal inflow by 40% allowing a better thermal conduction,
which contributes to a better ablation efficacy.15,23,24 Nevertheless,
treatment-related major complications are not negligible (3.5–
29%) and mortality occurs in up to 1.4% of the patients.15,24–26
Although the present study was limited by the relative small
sample size and its retrospective nature, the current reported
initial and sustained complete responses to LRFA, as well as the
results in overall survival, are consistent with previous published
reports and comparable to pRFA.2,6,8,25,27
However, to the best of the authors’ knowledge, this is the first
study to report that LRFA for HCC adjacent to the gallbladder is
associated with a decreased ablation efficacy in terms of initial
and sustained complete tumour response. Pathological mecha-
nisms are still to be determined. Four routes have been described
for HCC dissemination: lymphogenous, hematogenous via the
portal venous system, direct invasion and peritoneal dissemina-
tion. In spite of the fact that none of the gallbladder specimens
in the current series showed HCC invasion at pathological
Table 4 Factors associated with initial complete response, sustained complete response and distant recurrence
Initial complete response
(n = 51 nodules)
Sustained complete response
(n = 51 nodules)
Distant recurrence
(n = 41 patients)
Yes
(n = 48)
No
(n = 3)
P Yes
(n = 36)
No
(n = 15)
P Yes
(n = 25)
No
(n = 16)
P
Cirrhosis aetiology
NS NS NS– HCV 34 3 27 10 19 9
– Non HCV 14 0 9 5 6 7
Child–Pugha
NS NS NS
– A 32 2 26 8 16 13
– B 12 1 7 6 7 2
– C 1 0 1 0 0 1
Main tumour size
NS NS NS
– < 2 cm (n = 18) 16 2 13 5 7 4
– 2.1–3 cm (n = 22) 21 1 16 6 14 5
– 3.1–5 (n = 11) 11 0 7 4 4 7
Number of nodules
NS NS NS
– Unicentric 30 2 24 8 17 15
Location
– Subcapsular 30 1b NS 26 5 0.010 16b 14 NS
– Adjacent to gallbladder 13 3 0.008 7 9 0.004 11 4 NS
– Adjacent to other viscera 7 0 NS 4 3 NS 3 4 NS
Initial complete response 22 16 NS
Sustained complete response 17 13 NS
aNo data in two patients.
bSubcapsular nodule in contact with gallbladder.
HCV, hepatitis C virus; NS, not significant.
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examination, it has previously been proposed the invasion of the
pericholecystic veins as the disseminating mechanism.28,29 The
lower rate of treatment efficacy in nodules adjacent to the gall-
bladder in the current series could be maybe explained by sat-
ellite lesions or thrombus involving those cholecystic veins of the
gallbladder bed (which might be exposed during cholecystec-
tomy), and therefore a more advanced disease not completely
treated by the LRFA zone. Moreover, cholecystectomy may have
artefacted ultrasound images precluding an adequate assessment
of the ablation zone.
In conclusion, this study demonstrates that LRFA of HCC is
safe and feasible and achieves excellent results in selected patients.
The laparoscopic approach should be the first-line technique for
RFA in subcapsular location as it minimizes the risk of tumoural
seeding and improves an initial complete response. Proximity to
gallbladder interferes in treatment efficacy as it is related to a lower
rate of initial complete response and lower rate of a sustained
complete response.
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